Australian Cancer Research Foundation Detector
The ACRF Detector enables the shape and function of proteins to be analysed on the Australian Synchrotron’s Micro Crystallography (MX2) beamline in a fraction of the time it took previously, providing a ten-fold increase in capacity crucial to accelerating cancer drug development.
ACRF’s investment in this key cancer research technology, available at only a handful of other synchrotron facilities around the world, will lead to better outcomes for people living with cancer.
By increasing the capacity for drug development research in Australia, it is Australians with cancer who will be the first to benefit as novel treatments move from laboratories into clinical trials at our public hospitals.
The ACRF Detector at the Australian Synchrotron was officially opened in March 2017.